Be protected from cervical cancer for less
Here's some good health news to start the holidays: GlaxoSmithKline (GSK) has made its cervical cancer vaccine more affordable and accessible to Filipinas who want protection from the disease.
In their efforts to protect more women from cervical cancer, GSK cut the price for their vaccine to 60 per cent its original price. "When we said that every woman deserves a chance against cervical cancer, we meant it. GSK Philippines is proud to achieve this important milestone of being the first country to make our cervical cancer vaccine affordable to more women," said GSK president and managing director Rick Gain.
Before the price cut, cervical cancer vaccine cost P4,000 to P6,500 per shot. Doctors recommend that females age 10 and up get the shot three times in six months.
Cervical cancer is the second most common cancer afflicting women worldwide, with 500,000 cases and 250,000 deaths occurring every year. Over 80 per cent of cases occur in developing countries such as the Philippines, where the disease is ranked as second most common cancer risk for Filipino women. However, the disease is preventable through vaccination and can be treated if diagnosed early.
Clinical data also showed that GSK's cervical cancer vaccine provides protection for nearly six and a half years, reportedly the longest duration of protection for a cervical cancer vaccine to date.
In their efforts to protect more women from cervical cancer, GSK cut the price for their vaccine to 60 per cent its original price. "When we said that every woman deserves a chance against cervical cancer, we meant it. GSK Philippines is proud to achieve this important milestone of being the first country to make our cervical cancer vaccine affordable to more women," said GSK president and managing director Rick Gain.
Before the price cut, cervical cancer vaccine cost P4,000 to P6,500 per shot. Doctors recommend that females age 10 and up get the shot three times in six months.
Cervical cancer is the second most common cancer afflicting women worldwide, with 500,000 cases and 250,000 deaths occurring every year. Over 80 per cent of cases occur in developing countries such as the Philippines, where the disease is ranked as second most common cancer risk for Filipino women. However, the disease is preventable through vaccination and can be treated if diagnosed early.
Clinical data also showed that GSK's cervical cancer vaccine provides protection for nearly six and a half years, reportedly the longest duration of protection for a cervical cancer vaccine to date.
Comments